Introduction {#sec1-1}
============

Chronic kidney disease (CKD) is one of the serious public health problems, characterized by structural and functional abnormalities in the kidney. CKD affects millions of people worldwide with a prevalence of 800 per million populations in India. Diabetes mellitus and hypertension are the common underlying diseases associated with CKD.\[[@ref1]\] The major complications of CKD are anemia, cardiovascular disease, renal osteodystrophy, and metabolic acidosis.\[[@ref2]\] These complications are mainly responsible for the increased morbidity and mortality of the disease.\[[@ref2]\] As the prevalence of patients with CKD is predicted to rise, it is of paramount importance to look for therapeutic approaches to control and treat CKD.

Metabolic acidosis is one of the earliest hallmarks of the CKD. Metabolic acidosis arises due to the inability of the kidney to synthesize ammonia and excrete hydrogen ions. This often results in adverse effects such as bone resorption and osteopenia,\[[@ref3][@ref4][@ref5][@ref6]\] increased muscle protein catabolism,\[[@ref7][@ref8][@ref9][@ref10][@ref11][@ref12]\] exacerbation of secondary hyperparathyroidism,\[[@ref13][@ref14]\] increased risk of acute illness due to reduced respiratory reserve and exhaustion of body buffer systems,\[[@ref15]\] and systemic inflammation.\[[@ref16][@ref17]\] Thus, overcoming metabolic acidosis is necessary for relieving complications of CKD. Earlier reports have suggested the role of oral bicarbonate supplementation in correcting the metabolic acidosis.\[[@ref18][@ref19]\] However, we are still in dark in achieving more success toward this. Therefore, in this study, we sought to analyze the effect of oral supplementation of bicarbonate on the progression of CKD.

Materials and Methods {#sec1-2}
=====================

Site and study design {#sec2-1}
---------------------

This was a parallel randomized controlled trial, carried out at K. S. Hegde Medical Academy, Mangaluru, India. The approval from the ethical committee was obtained for the study INST.EC/E.C/36/2012-13. Informed consent was taken from the patients.

Study population {#sec2-2}
----------------

Patients with CKD who were visiting Justice K. S. Hegde Charitable Hospital, Mangalore, were considered as the study subjects. A total of 67 patients participated in the study. Patients were randomly grouped into two groups through block randomization. The first group of patients received oral sodium bicarbonate, whereas the second group of patients was on standard therapy without oral sodium bicarbonate supplementation.

The inclusion criteria for the selection of subjects included the following:

Age: \>18 yearsEstimated glomerular filtration rate (eGFR): 15--30 mL/min/1.73 m^2^Serum bicarbonate: 10--20 mM/LClinical condition: stable.

The exclusion parameters are as follows:

Patients on steroid therapyCongestive heart failureUncontrolled hypertension (\>150/90 mmHg)Cognitive impairmentOngoing sepsisMorbid obesity \[body mass index (BMI) ≥40 kg/m^2^\]Malignancies.

Group 1 received 600 mg sodium bicarbonate orally three times a day. The dosage was increased accordingly to achieve bicarbonate levels \>23 mmol/L. All the subjects were followed up on 6 and 9 months. Parameters such as weight, height, and BMI of all the subjects were measured. Also, the subjects were checked for any underlying renal diseases. Venous blood collected from each subject under the aseptic condition and the serum was collected as described by AlRawi 2011.\[[@ref20]\] Serum bicarbonate was quantified by following enzymatic procedures using cobas kit (Roche Diagnostics, Switzerland) as per the manufacturer\'s instructions. The consumption of NADH in the reaction is quantified by measuring absorbance at 340 nm on an automated analyzer (Roche Diagnostics), which is proportional to the bicarbonate concentration in the serum. The concentration of creatinine in serum was analyzed on an automated analyzer using the Roche/cobas CREJ2 assay based on Jaffe\'s method. The analysis was performed by measuring the absorbance at 505 nm using a green filter. eGFR was measured from the serum creatinine level by applying the MDRD formula (equation 1) using computer software.

eGFR = 186 × serum creatinine^−1.154^ × age^−0.203^ × 0.742 (only if female) (Equation 1)

Photometrical estimation of albumin in serum was performed on an automated analyzer using a kit developed for Roche/cobas c systems. Albumin in serum binds with bromocresol green to form a blue-green complex at pH 4.1, which is measured at 630 nm.

Nutritional assessment {#sec2-3}
----------------------

*For mid-arm circumference (MAC)* subject\'s elbow was flexed to 90° and the midpoint between the tip of acromion and olecranon process was located. The MAC was measured with the subject standing erect by recording the arm circumference with the arm relaxed and elbow extended.

*Corrected arm muscle area (CAMA)* was measured from MAC using equation 2.

CAMA = {\[(MAC − (π × TSF)\]^2/^ 4π} -- 10 (Equation 2)

Triceps skinfold (TSF) was measured in the midline of the posterior aspect of the arm, over the triceps muscle, at a point midway between the acromion process and the olecranon process, using the Harpenden skinfold caliper.

Muscle mass (kg) = Height in cm × (0.0264 + (0.0029 × CAMA)) (Equation 3)

Statistical analysis {#sec2-4}
--------------------

Comparison of the parameters was done using one-way analysis of variance. Student\'s *t*-test was used to calculate the significance between means. Significance was established upon a *P* value of less than 0.05.

Results {#sec1-3}
=======

A total of 67 patients were divided into two groups. Group 1 consisted of 33 subjects, out of which 23 (69.7%) were males and 10 (30.3%) were females. Group 2 included 34 patients, of which 25 (73.53%) were males and 9 (26.47%) were females. Out of 67 participants, 5 (7.5%) were of the age less than or equal to 40 years. A total of 31 patients (46.3%) were between 41 and 60 years of age, while the same number of subjects were of the age range 61--80 years. Groups 1 and 2, respectively, consist of 39.4% and 52.9% of subjects in the age range 41--60 years. Furthermore, patients of age range 61--80 years in groups 1 and 2 were 51.5% and 41.2%, respectively. The etiology of patients with CKD in both the groups is represented in [Table 1](#T1){ref-type="table"}.

###### 

Diagnosis etiology of CKD in study subjects

  Diagnosis                                 Group   Total   
  ----------------------------------------- ------- ------- -------
  Hypertension                              7       8       15
                                            21.2%   23.5%   22.4%
  Hypertension and diabetes                 10      11      21
                                            30.3%   32.4%   31.3%
  Hypertension, Diabetes and other causes   3       3       6
                                            9.1%    8.8%    9.0%
  Hypertension and other causes             4       6       10
                                            12.1%   17.6%   14.9%
  Diabetes                                  3       0       3
                                            9.1%    0%      4.5%
  Diabetes and other causes                 3       6       9
                                            9.1%    17.6%   13.4%
  Other causes                              3       0       3
                                            9.1%    0%      4.5%
  Total                                     33      34      67
                                            100%    100%    100%

Fisher's exact test *P*=0.327. CKD: Chronic kidney disease

The mean weight of groups 1 and 2 was 58.18 and 61.97 kg, respectively, whereas the mean height of groups 1 and 2 was 161.71 and 162.12 cm, respectively. The mean BMI of group 1 was 22.40 and of group 2 was 23.48. It was observed that the difference of mean values of weight, height, and BMI between both the groups was not statistically significant.

Quantification of serum bicarbonate {#sec2-5}
-----------------------------------

The bicarbonate concentrations of groups 1 and 2 at baseline were in agreement \[[Figure 1](#F1){ref-type="fig"}\]. The mean bicarbonate levels of groups 1 and 2 patients were 16.62 and 16.84 mEq/L, respectively \[[Table 2](#T2){ref-type="table"}\]. After 6 months, the bicarbonate level of group 1 significantly increased to 18.02 mEq/L, which was further increased to 19.77 mEq/L after 9 months (*P* = 0.001). In contrast, the bicarbonate level in group 2 remains unchanged after 6 and 9 months (*P* = 0.301).

![Estimation of serum bicarbonate levels at different time points in both groups](IJN-30-91-g001){#F1}

###### 

Mean serum bicarbonate, eGFR, serum albumin, and muscle mass levels at baseline, 6, and 9 months in group 1 and group 2

  Parameter                 Group         *n*   Mean    Standard deviation   Lower boundary   Upper boundary   ANOVA *F*   *P*
  ------------------------- ------------- ----- ------- -------------------- ---------------- ---------------- ----------- ---------
  HCO~3~ (mEq/L)            Group 1                                                                                        \<0.001
                            Baseline      33    16.62   3.05                 15.54            17.70            23.867      
                            At 6 months   31    18.48   1.24                 18.02            18.94                        
                            At 9 months   30    19.77   1.86                 19.07            20.47                        
                            Group 2                                                                                        0.301
                            Baseline      34    16.84   2.17                 16.08            17.60            1.226       
                            At 6 months   33    16.85   1.46                 16.33            17.37                        
                            At 9 months   28    16.32   1.80                 15.62            17.02                        
  eGFR (mL/min/1.73 m^2^)   Group 1                                                                                        
                            Baseline      33    22.39   4.08                 20.94            23.84            0.116       0.736
                            At 6 months   31    22.66   5.72                 20.56            24.76                        
                            At 9 months   30    22.65   5.92                 20.44            24.86                        
                            Group 2                                                                                        
                            Baseline      34    21.21   4.37                 19.68            22.73            5.060       0.010
                            At 6 months   33    20.06   4.93                 18.32            21.81                        
                            At 9 months   28    19.88   3.92                 18.36            21.41                        
  Serum albumin (g/dL)      Group 1                                                                                        0.000
                            Baseline      33    4.05    0.59                 3.84             4.27             9.716       
                            At 6 months   31    4.24    0.47                 4.07             4.41                         
                            At 9 months   30    4.34    0.44                 4.18             4.51                         
                            Group 2                                                                                        
                            Baseline      34    4.13    0.45                 3.97             4.28             1.149       0.325
                            At 6 months   33    4.04    0.42                 3.89             4.18                         
                            At 9 months   28    4.02    0.54                 3.81             4.23                         
  Muscle mass (kg)          Group 1                                                                                        
                            Baseline      33    20.03   4.74                 18.35            21.71            8.833       0.000
                            At 6 months   31    21.54   4.99                 19.71            23.37                        
                            At 9 months   30    21.52   4.57                 19.81            23.23                        
                            Group 2                                                                                        
                            Baseline      34    21.96   5.67                 19.99            23.94            2.987       0.046
                            At 6 months   33    21.25   4.40                 19.69            22.81                        
                            At 9 months   28    20.29   4.86                 18.40            22.17                        

eGFR: Estimated glomerular filtration rate; ANOVA: Analysis of variance

*Post hoc* analysis confirmed that the difference in the serum bicarbonate levels of group 1 subjects between different time intervals was statistically significant \[[Table 3](#T3){ref-type="table"}\]. The highest difference in the bicarbonate levels was found between baseline and 9 months\' subjects (mean difference of − 3.330, *P* \< 0.0001). Furthermore, when both the groups were compared, the difference in the serum bicarbonate value at different time points is highly significant \[[Table 4](#T4){ref-type="table"}\].

###### 

Comparison of serum bicarbonate, eGFR, serum albumin, and muscle mass levels at different timelines in both groups by *post hoc* analysis by Bonferroni test

  Parameter               Group                   Mean difference         Standard error   Change (%)   *P*      
  ----------------------- ----------------------- ----------------------- ---------------- ------------ -------- -------
  HCO3                    Group 1                 Baseline and 6 months   −2.157           0.553        −11.21   0.002
  Baseline and 9 months   −3.330                  0.567                   −18.97           \<0.001               
  6 and 9 months          −1.173                  0.299                   −6.98            0.001                 
  eGFR                    Group 2                 Baseline and 6 months   0.705            0.704        5.40     0.976
  Baseline and 9 months   2.117                   0.694                   6.24             0.015                 
  6 and 9 months          1.412                   0.633                   0.88             0.102                 
  Serum albumin           Group 1                 Baseline and 6 months   −0.217           0.066        −4.62    0.009
  Baseline and 9 months   −0.283                  0.084                   −7.12            0.006                 
  6 and 9 months          −0.67                   0.046                   −2.39            0.476                 
  Muscle mass             Group 1                 Baseline and 6 months   −1.757           0.375        −7.54    0.000
  Baseline and 9 months   −1.394                  0.569                   −7.46            0.046                 
  6 and 9 months          0.364                   0.346                   0.08             0.907                 
  Group 2                 Baseline and 6 months   0.725                   0.544            3.23         0.582    
  Baseline and 9 months   1.219                   0.452                   7.64             0.036                 
  6 and 9 months          0.494                   0.504                   4.55             1.000                 

eGFR: Estimated glomerular filtration rate

###### 

Comparison of serum bicarbonate, eGFR, serum albumin, and muscle mass levels between group 1 and group 2 by two-sample *T*-test

  Parameter              Time points            Group     Mean difference   Standard error   *P*
  ---------------------- ---------------------- --------- ----------------- ---------------- -------
  HCO3                   Baseline to 6 months   Group 1   −2.157            0.553            0.006
  Group 2                −0.04                  0.255                                        
  Baseline to 9 months   Group 1                −3.330    0.567             0.000            
  Group 2                0.414                  0.375                                        
  6 to 9 months          Group 1                −1.173    0.299             0.000            
  Group 2                0.418                  0.277                                        
  eGFR                   Baseline to 6 months   Group 1   −0.096            0.704            0.164
  Group 2                0.705                  0.704                                        
  Baseline to 9 months   Group 1                0.211     0.680             0.045            
  Group 2                2.117                  0.694                                        
  6 to 9 months          Group 1                0.307     0.563             0.103            
  Group 2                1.412                  0.633                                        
  Serum albumin          Baseline to 6 months   Group 1   −0.217            0.066            0.000
  Group 2                0.039                  0.040                                        
  Baseline to 9 months   Group 1                −0.283    0.084             0.001            
  Group 2                −0.096                 0.070                                        
  6 to 9 months          Group 1                −0.067    0.046             0.001            
  Group 2                0.057                  0.076                                        
  Muscle mass            Baseline to 6 months   Group 1   −1.757            0.375            0.000
  Group 2                0.725                  0.544                                        
  Baseline to 9 months   Group 1                −1.394    0.569             0.001            
  Group 2                1.219                  0.452                                        
  6 to 9 months          Group 1                0.364     0.346             0.001            
  Group 2                0.494                  0.504                                        

eGFR: Estimated glomerular filtration rate

Effect of bicarbonate supplementation on eGFR {#sec2-6}
---------------------------------------------

The effect of bicarbonate supplementation on eGFR is shown in [Figure 2](#F2){ref-type="fig"}. The baseline eGFR values in group 1 and 2 subjects were 22.39 and 21.20 mL/min/1.73 m^2^, respectively. The difference between these values was not significant (*P* = 0.257). Similarly, no significant difference was observed in group 1 after 6 and 9 months \[[Table 2](#T2){ref-type="table"}\]. The mean eGFR of group 1 patients after 6 and 9 months was equivalent to baseline. In group 2, the eGFR was decreased significantly (*P* = 0.01) upon time. The mean eGFR after 6 months of duration was 20.06 mL/min/1.73 m^2^, which further reduced to 19.88 mL/min/1.73 m^2^ after 9 months. *Post hoc* analysis \[Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}\] corroborated that in patients without bicarbonate supplementation (group 2), a significant reduction in the eGFR with a change of about 6.2% from baseline to 9 months was observed (*P* = 0.045).

![Estimation of eGFR at different time points in both groups](IJN-30-91-g002){#F2}

Estimation of serum albumin {#sec2-7}
---------------------------

Serum albumin levels in both the groups were analyzed. The group without any bicarbonate supplementation did not show any significant change in the serum albumin levels \[[Figure 3](#F3){ref-type="fig"}\]. There was a slight decrease in the albumin level of group 2 patients at 6 and 9 months (4.04 and 4.10 g/dL, respectively) compared with baseline (4.13 g/dL). Interestingly, group 1 patients displayed increased serum albumin levels compared with baseline (*P* = 0.0001) \[[Table 2](#T2){ref-type="table"}\]. In group 1, statistically significant difference in the serum albumin levels between different time intervals was observed [Table 3](#T3){ref-type="table"}, wherein baseline to 9 months was highly significant (*P* = 0.006). When both the groups subjects were compared, the difference in the serum bicarbonate value at different time points was found to be highly significant \[[Table 4](#T4){ref-type="table"}\].

![Estimation of serum albumin levels at different time points in both groups](IJN-30-91-g003){#F3}

Muscle mass {#sec2-8}
-----------

In patients with bicarbonate supplementation, significant improvement in muscle mass was observed after a period of 6 and 9 months \[[Table 2](#T2){ref-type="table"}\]. The muscle mass of groups 1 and 2 at baseline was 20.03 and 21.96 kg, respectively. After 6 months, the muscle mass was increased in group 1 to 21.54 kg and decreased in group 2 to 21.25 kg. After 9 months, the muscle mass further decreased to 20.29 kg in group 2. These changes in the muscle mass were statistically significant \[[Figure 4](#F4){ref-type="fig"}\].

![Estimation of muscle mass at different time points in both groups](IJN-30-91-g004){#F4}

When compared between time points, significant improvement in the muscle mass was observed from baseline to 6 months (7.54%) and baseline to 9 months (7.46%) in group 1 \[[Table 3](#T3){ref-type="table"}\]. However, no significant improvement was found between 6 and 9 months. In group 2, a significant decrease in muscle mass was observed from baseline to 9 months (7.64%). But no significant changes were noticed between baseline and 6 months, as well as between 6 and 9 months subjects. Furthermore, when compared between the groups \[[Table 4](#T4){ref-type="table"}\], at all time points, the muscle mass was significantly different (*P* = 0.001).

Discussion {#sec1-4}
==========

High prevalence of CKD in India is a matter of concern due to its associated mortality, morbidity, and complications. Besides diabetes and hypertension, some of the issues which contribute to CKD in India include pollutants, nephrotoxins, poor sanitation, water contamination, consanguinity, and genetic inbreeding.\[[@ref21]\] Since the population of patients with diabetes and hypertension in India is growing, management of CKD has become highly important.

Strategies to manage CKD involve delaying the progression of the disease by modifying some of the associated factors. Such modifiable factors which were focused earlier to manage CKD are hypertension, glycemic control, and proteinuria.\[[@ref22][@ref23]\] Research over the last decade has identified metabolic acidosis as one of the potential factors causing progression of the disease. Typically, serum bicarbonate values during metabolic acidosis condition will be less than 22 mmol/L.\[[@ref24][@ref25]\] The beneficial effect of oral bicarbonate supplementation on kidney function was reported earlier.\[[@ref26][@ref27]\] We investigated the role of bicarbonate supplementation in relieving disease complications in patients with CKD. Time-dependent significant increase in the mean bicarbonate levels of group 1 was observed, while no change was reported in group 2. Thus, it was very clear that oral supplementation of bicarbonate decreases the metabolic acidosis during CKD condition, which was also suggested by earlier report.\[[@ref18]\]

It is well-known that a decrease in eGFR is very common in patients with CKD. Actually, eGFR rate is an indicator to analyze the severity of disease and to monitor the treatment response.\[[@ref28]\] A previous report by Krolewski *et al*. has confirmed an eGFR loss of ≥3.3% per year in CKD.\[[@ref29]\] In our study, bicarbonate supplementation has resulted in the maintenance of eGFR to its baseline value, wherein eGFR was deteriorated in the group without bicarbonate supplementation. This is in agreement with an earlier study which also showed a slower decline in the eGFR post bicarbonate supplementation.\[[@ref26]\]

A study by Ballmer *et al*.\[[@ref30]\] validated that metabolic acidosis results in increased nitrogen excretion and decreased albumin synthesis due to increased protein degradation. Consequently, correction of metabolic acidosis in such patients is important to prevent protein (muscle) wasting. de Brito-Ashurst *et al*.\[[@ref27]\] have observed that sodium bicarbonate supplementation was associated with better nutritional status with improved dietary protein intake and decreased protein catabolism in parallel with increased serum albumin and lean body mass. The results of our study support the above conclusion since an improvement in the serum albumin level and the muscle mass in patients who were supplemented with oral sodium bicarbonate was evidenced. Taken together, bicarbonate supplementation helps in delaying the progression of CKD by relieving the effects of metabolic acidosis. Thus, it can be useful in the management of CKD.

Conclusion {#sec1-5}
==========

In conclusion, the serum bicarbonate level of subjects was increased upon oral bicarbonate supplementation. Oral supplementation also resulted in the maintenance of GFR and increase in serum albumin level among patients with CKD. Furthermore, bicarbonate supplementation also improved the muscle mass in patients with CKD. All these suggest the effect of bicarbonate in relieving the metabolic acidosis and thereby its possible role in the management of CKD progression.
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